Prestige BioPharma Limited (KRX:950210)
3,690.00
-185.00 (-4.77%)
Nov 20, 2026, 3:30 PM KST
Prestige BioPharma Market Cap
Prestige BioPharma has a market cap or net worth of 44.35 billion as of November 20, 2026. It is the 32,625th most valuable company in the world and the 1,822nd biggest in South Korea. Its market cap has decreased by 69.50% in one year.
Market Cap
44.35B
Enterprise Value
157.50B
Revenue
26.07B
Global Rank
Country Rank
#1,822 South Korea
PE Ratio
n/a
ChartMarket Cap Chart
Since May 28, 2021, Prestige BioPharma's market cap has decreased from 360.58B to 44.35B, a decrease of -87.70%. That is a compound annual growth rate of -31.75%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 20, 2026 | 44.35B | -71.28% |
| Dec 30, 2025 | 154.45B | -14.96% |
| Dec 30, 2024 | 181.61B | 59.39% |
| Dec 28, 2023 | 113.94B | 29.33% |
| Dec 29, 2022 | 88.10B | -64.84% |
| Dec 30, 2021 | 250.60B | -30.50% |
| May 28, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Anterogen.Co.,Ltd. | 130.98B |
| MedPacto | 124.25B |
| HLB Therapeutics | 104.00B |
| Vaxcell-Bio Therapeutics | 82.21B |
| Genexine | 80.82B |
| iNtRON Biotechnology | 76.46B |
| Amicogen | 62.70B |
| GeneOne Life Science | 48.42B |